Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

264
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
264

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Real‑World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis.

Rheumatology and therapy·2025
Same author

Cellular interactions in maintaining an inflammatory microenvironment in rheumatoid arthritis.

Molecular immunology·2025
Same author

Methotrexate toxicity: the need for vigilance in prescribing and monitoring.

Internal medicine journal·2025
Same author

Validity and reliability study of the Turkish version of the Empathy Quotient- 8 in Turkish university students.

Psicologia, reflexao e critica : revista semestral do Departamento de Psicologia da UFRGS·2025
Same author

The Relationship Between Patient-Reported Quality of Life and Physician-Derived Clinical Outcomes in Rheumatoid Arthritis in the Australian OPAL Dataset.

International journal of rheumatic diseases·2025
Same author

Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis.

Rheumatology and therapy·2025

Related Experiment Video

Updated: Oct 26, 2025

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

1.3K

Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL

Hedley Griffiths1, Tegan Smith2, Christopher Mack3

  • 1H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; hedley@brservice.com.au.

The Journal of Rheumatology
|August 2, 2021
PubMed
Summary

Biologic disease-modifying antirheumatic drug (bDMARD) therapy effectively reduced ankylosing spondylitis disease activity in Australian patients. First-line bDMARD treatment showed sustained persistence up to 8 years, longer than subsequent therapies.

Keywords:
ankylosing spondylitisbiologic therapydisease-modifying antirheumatic drugsmedication persistence

More Related Videos

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.6K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K

Related Experiment Videos

Last Updated: Oct 26, 2025

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

1.3K
A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.6K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Ankylosing spondylitis (AS) is a chronic inflammatory condition.
  • Biologic disease-modifying antirheumatic drugs (bDMARDs) are crucial for managing AS.
  • Understanding real-world treatment response and persistence is vital for optimizing patient outcomes.

Purpose of the Study:

  • To evaluate treatment response and persistence of bDMARD therapy in an Australian ankylosing spondylitis cohort.
  • To compare persistence rates across different bDMARDs and lines of therapy.

Main Methods:

  • Retrospective, noninterventional cohort study using the OPAL dataset (August 2006-September 2019).
  • Patients classified as bDMARD initiators or bDMARD-naïve.
  • Descriptive statistics and Kaplan-Meier methods for persistence analysis.

Main Results:

  • 5048 AS patients identified; 2597 initiated bDMARDs.
  • All bDMARDs significantly reduced disease activity.
  • Median persistence: 96 months (first-line), 19 months (second-line), 15 months (third-line).
  • Golimumab showed longest persistence; etanercept showed shortest.
  • Differences in persistence observed for etanercept and adalimumab based on prescription period.

Conclusions:

  • bDMARDs are effective in reducing AS disease activity in a real-world setting.
  • Sustained treatment persistence is achievable with first-line bDMARDs.
  • Further research is warranted to inform treatment recommendations based on persistence data.